Efficacy and Safety of VDPHL01 in Males With AGA (NCT06724614)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). The first 7 visits will be part of the placebo-controlled period. The next 3 visits will be part of the treatment extension phase. All subjects will receive active drug in the treatment extension phase.
Who can join: Review the eligibility criteria below.
Location: Site 36 — Birmingham, Alabama
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (44 Sites)
Showing the first 25 of 44 sites.
- Site 36 — Birmingham, Alabama
- Site 28 — Phoenix, Arizona
- Site 30 — Fort Smith, Arkansas
- Site 35 — Rogers, Arkansas
- Site 07 — Fountain Valley, California
- Site 02 — Fremont, California
- Site 34 — Sherman Oaks, California
- Site 21 — Vista, California
- Site 05 — Castle Rock, Colorado
- Site 24 — Englewood, Colorado
- Site 17 — Aventura, Florida
- Site 25 — Brandon, Florida
- Site 42 — Hollywood, Florida
- Site 03 — Tampa, Florida
- Site 43 — Atlanta, Georgia
- Site 31 — Boise, Idaho
- Site 23 — Rolling Meadows, Illinois
- Site 15 — Indianapolis, Indiana
- Site 32 — New Albany, Indiana
- Site 27 — West Lafayette, Indiana
- Site 41 — Baton Rouge, Louisiana
- Site 13 — Covington, Louisiana
- Site 12 — Metairie, Louisiana
- Site 22 — Brighton, Massachusetts
- Site 26 — Clarkston, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Androgenetic Alopecia
- Safety and Efficacy of VDPHL01 in Males With AGA — Birmingham, Alabama
- Safety and Efficacy of VDPHL01 in Males and Females With AGA — San Diego, California
- Use of Botulinum Toxin in the Treatment of Androgenic Alopecia — Edina, Minnesota
- XVIE to Treat Androgenetic Alopecia (AGA) — Orlando, Florida
Explore by condition: All Androgenetic Alopecia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.